Recipharm has announced that it has been contracted by ViroPharma to complete commercial scale-up manufacture of Plenadren® (Hydrocortisone, Modified Release Tablet) - used for the treatment of adrenal insufficiency in adults.
Under the contractual terms, ViroPharma is also investing in new equipment in order to increase the manufacturing capacity for Plenadren in order to support commercial product launches across Europe.
The new agreement follows the completion of Recipharm’s initial scale-up contract with DuoCort Pharma AB - a recent acquisition for ViroPharma following Plenadren’s® receipt of European Marketing Authorization and Confirmation of Orphan Drug Designation.
Additionally, Recipharm will also be able to use the new equipment for other projects, with ViroPharma retaining its status as highest priority customer.
Helene Fehrm, General Manager of Recipharm Stockholm, said: “We are really pleased ViroPharma has chosen to work together with Recipharm for commercial scale up following the highly successful relationship we had developed with DuoCort. We look forward to building a long term relationship with ViroPharma for its production. This investment and the work we are doing for ViroPharma will give us further valuable experience in tablet manufacturing with API in the coating - a unique advantage over conventional approaches - both for Plenadren® itself and other customers moving forwards.”
Marco Carli, General Manager, Principal & Senior Director, Supply Chain, Europe added: “We are delighted to continue DuoCort’s long-standing relationship with Recipharm as they have been a key component in the development process for Plenadren®, and we look forward to building a long term relationship.”